Specifically, the Food and Drug Administration (FDA) and European Medicines Agency (EMA) approved bladder tumor antigen (BTA), nuclear matrix protein 22 (NMP22), ImmunoCyt/uCyt+, and UroVysion as urinary biomarkers for the detection and surveillance of urothelial carcinomas [8]. The gene discussed is NUMA1; the disease is neoplasm.